Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Leuven, Belgium – Oxurion NV, a biopharmaceutical company, announced the receipt of transparency notifications from Atlas Special Opportunities II LLC. In accordance with Belgian transparency legislation, Oxurion has been informed of significant changes in Atlas's shareholdings.

On May 15, 2025, it was notified that as of May 8, 2025, Atlas held 202,731 shares, representing a stake of less than 5% of the 4,634,663 shares outstanding as of that date, following a share sale. On the same day, it was reported that as of May 12, 2025, Atlas held 1,724,103 shares, exceeding the 25% threshold of the 6,156,035 shares, following a purchase.

Oxurion is headquartered in Leuven and specializes in the development of advanced ophthalmic therapies. For more details, see the company's annual report.